Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$118.64 USD

118.64
8,516,713

+0.35 (0.30%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $118.77 +0.13 (0.11%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know

In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

Here's Why Merck (MRK) Gained But Lagged the Market Today

Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Merck (MRK) Stock Moves -0.63%: What You Should Know

Merck (MRK) closed the most recent trading day at $117.84, moving -0.63% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More

European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.

Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug

The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma

MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.

Merck (MRK) Advances But Underperforms Market: Key Facts

In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.

Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs

LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.

Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate

Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.

Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?

MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.

Do Options Traders Know Something About Merck (MRK) Stock We Don't?

Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.

The Zacks Analyst Blog Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of Distinction

Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of Distinction are included in this Analyst Blog.